A phase II clinical trial of tadekinig alfa in patients with refractory AOSD (127) reported about half of the patients had a normal body temperature with CRP levels decreased to 50% of their baseline levels or <5 mg/L 3 weeks after starting tadekinig alfa. Here, CRP is linked to adult-onset Still disease.